Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov;24(11):1248-50.
doi: 10.1007/s11606-009-1095-5. Epub 2009 Sep 22.

Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment

Patricia R Hebert  1 , Wendy R Schneider, Charles H Hennekens
Affiliations
Review

Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment

Patricia R Hebert et al. J Gen Intern Med. 2009 Nov.

Abstract

Background: The American Heart Association Guidelines recommend aspirin for all apparently healthy individuals whose 10-year risk of a first coronary heart disease (CHD) event is >10%.

Methods: The United States (US) Preventive Services Task Force (USPSTF) has recently updated its guidelines to encourage men 45 to 79 years and women 55 to 79 years to use aspirin when the potential benefit outweighs the potential harm. In addition, in some US guidelines, diabetes is considered to be a CHD risk equivalent.

Results: Two recently published trials, the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) and the Prevention of Progression of Arterial Disease and Diabetes (POPADAD), concluded that aspirin did not reduce risks of CHD. Both JPAD and POPADAD had inadequate statistical power. Reliable randomized evidence is necessary to provide a sufficient totality of evidence about benefits and risks among diabetics.

Conclusion: At present, astute individual clinical judgments are necessary.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '2676237', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/2676237/'}]}
    2. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749–56. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1136/bmj.324.7329.71', 'is_inner': False, 'url': 'https://doi.org/10.1136/bmj.324.7329.71'}, {'type': 'PMC', 'value': 'PMC64503', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC64503/'}, {'type': 'PubMed', 'value': '11786451', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11786451/'}]}
    2. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86. - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.amjcard.2006.04.012', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.amjcard.2006.04.012'}, {'type': 'PubMed', 'value': '16950176', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16950176/'}]}
    2. Bartolucci AA, Howard G. Meta-analyses of data from six preliminary primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98:746–50. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1161/01.CIR.0000020190.45892.75', 'is_inner': False, 'url': 'https://doi.org/10.1161/01.cir.0000020190.45892.75'}, {'type': 'PubMed', 'value': '12119259', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12119259/'}]}
    2. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388–91. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '19293072', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/19293072/'}]}
    2. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US preventive services task force recommendation statement. Ann Intern Med. 2009;150:396–404. - PubMed

Publication types